Healthcare
Medical
Pharmaceutical

Novartis

$93.17
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.

-$0.12 (-0.13%) Today
$0.00 (0.00%) After Hours

Why Robinhood?

You can buy or sell Novartis and other stocks, options, ETFs, and crypto commission-free!

About

Novartis AG, also called Novartis, is a holding company, which engages in the development, manufacture, and marketing of healthcare products. It operates through the following four segments: Innovative Medicines, Alcon, Sandoz, and Corporate. Read More The Innovative Medicines segment researches, develops, manufactures, distributes and sells patented pharmaceuticals, and is composed of two business units: Novartis Oncology and Novartis Pharmaceuticals. The Alcon segment researches, develops, manufactures, distributes and sells eye care devices and vision care. The Sandoz segment develops, manufactures and markets finished dosage form medicines as well as intermediary products including active pharmaceutical ingredients. The Corporate segment refers to group management and central services. The company was founded on February 29, 1996 and is headquartered in Basel, Switzerland.

Employees
125,161
Headquarters
Basel, Basel-Stadt (Basle Town)
Founded
1996
Market Cap
215.61B
Price-Earnings Ratio
17.18
Dividend Yield
2.15
Average Volume
2.05M
High Today
$93.22
Low Today
$92.71
Open Price
$93.08
Volume
732.88K
52 Week High
$93.62
52 Week Low
$72.30

Collections

Healthcare
Medical
Pharmaceutical
Manufacturing
Health
Technology

News

Yahoo Finance7h

Novartis' (NVS) Alcon Acquired PowerVision for $285 Million

Novartis NVS announced that its eye-care unit, Alcon acquired privately-held, U.S.-based medical device development company, PowerVision, Inc.

33
Seeking Alpha16h

Sandoz acquires PowerVision for $285M

Novartis (NYSE:NVS) unit Sandoz has acquired fluid-based intraocular lens maker PowerVision for $285M. It can earn additional payments based on the achievement of certain regulatory and commercial milestones starting in 2023. Alcon says it reaffirms its 2023 financial outlook provided in Q4 2018. NVS is down a fraction premarket....

50
Markets Insider21h

Novartis' Alcon Acquires PowerVision

(RTTNews) - Alcon, the global leader in eye care and a division of Novartis, announced today that it has acquired PowerVision, Inc.

15

Earnings

$1.18
$1.23
$1.27
$1.32
Q2 2017
Q3 2017
Q4 2017
Q1 2018
Q2 2018
Q3 2018
Q4 2018
Q1 2019
Estimated
Actual
Expected Apr 24, Pre-Market
All investments involve risk and the past performance of a security, or financial product does not guarantee future results or returns. Securities offered through Robinhood Financial LLC, member FINRA/SIPC. To learn more about the information provided on this page, please see our Web Disclosures.